Show Notes
A recent paper just dropped claiming an injection can cut heart attack risk by 25%—even for those who have never had one before. But is this a medical breakthrough or just expensive hype? In this episode, I’m diving deep into the Vesalius trial to separate the science from the headlines.
We’ll break down how PCSK9 inhibitors work (using a baseball analogy, of course), analyze the impressive relative risk reduction, and honestly discuss the "gray areas" like mortality benefits and the diversity gap in the data. My goal isn't to be a guru, but to help you cut through the noise so you can make evidence-informed decisions about your heart health. Let's dive in.
Stop stressing over every health detail & start living! My FREE 'Necessary Nine' PDF cuts through the noise, giving you the essential things you need for a healthy life.
➡️ Download Here: https://www.jrennickemd.com/necessaryninepdf
CHAPTERS: 00:00 - Intro 00:30 - Nerding Out on History: Statins & Previous Trials 01:03 - The PCSK9 Context: FOURIER & ODYSSEY 02:40 - Mechanism of Action: The "Catcher's Mitt" Analogy 03:47 - Vesalius Trial Design & Demographics 06:06 - The Endpoints: What is MACE? 07:16 - Addressing the "Big Pharma" Funding 08:28 - Primary Results: LDL Drop & 25% Reduction 09:34 - Absolute Risk vs. Relative Risk (The Real Numbers) 10:12 - Number Needed to Treat (NNT) 11:13 - The Mortality Question: Did it Save Lives? 12:06 - Safety Profile: Diabetes, Brain Fog & Muscle Pain 13:16 - Limitation 1: The Mortality "Provocative Signal" 13:57 - Limitation 2: The Ezetimibe Head-Scratcher 15:23 - Limitation 3: The Diversity Gap 15:52 - Bottom Line: Guidelines, "Big Rocks" & The Future
SELECTED REFERENCES: https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 https://www.nejm.org/doi/full/10.1056/NEJMoa1801174 https://www.nejm.org/doi/full/10.1056/NEJMoa1615664
*Disclaimer* This podcast is for entertainment, education, and informational purposes only. The topics discussed should not solely be used to diagnose, treat , or prevent any condition. The information presented here was created with an evidence based approach, but you please keep in mind that science is always changing and at the time of listening to this there may some new data that makes this information incomplete or inaccurate. Always seek the advice of your personal physician or qualified health care provider for questions regarding any medical condition.
More from Building Lifelong Athletes
In this episode, I try to cut through the noise of the cholesterol debate and walk through 150 years of vascular science. From ancient mummies to modern genetics, we examine how lipidology reached its consensus, the response-to-retention hypothesis, why ApoB particle count matters more than LDL cholesterol mass, and what landmark clinical trials reveal about cardiovascular risk.
Was Ancel Keys a visionary pioneer of preventive cardiology or the villain who triggered our metabolic health crisis? In this episode, I pull back the curtain on the real science, the controversial 1953 graph, hidden trial data, and sugar industry influence. We explore where Keys was decades ahead of his time, where his model failed, and what his legacy teaches us about navigating scientific dogma in clinical practice today.
In this episode, I break down the underlying science of cholesterol, lipoproteins, and heart disease. We'll cut through the online noise and examine how cholesterol actually moves through your bloodstream, why particle count (ApoB) matters more than total cholesterol weight, how statins and other medications work at the cellular level, and how plaque forms in atherosclerosis. Everything you need to understand lipidology 101.
Welcome back to the trenches! In our final breakdown of the 2026 ACC/AHA lipid guidelines, we are unpacking the pharmacology toolbox. From statins and ezetimibe to PCSK9 inhibitors and the nuances of side effects like SAMS, I want to give you the practical, evidence-informed strategies we need for our patients. We are all just trying to navigate this together.